{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.0","upperLimit":"50.3","value":"44.6"},{"groupId":"OG001","lowerLimit":"49.2","upperLimit":"60.0","value":"54.6"}]}],"title":"Disease-related Symptom Progression Rate (DRSPR)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.6","upperLimit":"97.5","value":"95.5"},{"groupId":"OG001","lowerLimit":"97.9","upperLimit":"99.9","value":"99.4"}]}],"title":"DRSPR Including Death and Investigator Progression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"411"}],"units":"Participants"}],"description":"Disease-related symptom progression rate (DRSPR)=a decrease of two points in the Functional Assessment of Cancer Therapy-Kidney Symptom Index - Disease Related Symptoms (FKSI-DRS) questionnaire relative to the participant's baseline FKSI-DRS score with no later increase above this threshold observed during the course of the study. The 9 items of the FKSI-DRS were summarized into a symptom scale ranging in score from 0 to 36, with 0 being the worst possible score and 36 being the best possible score. A single measure reporting a decrease of at least 2 units was considered disease-related symptom progression only if it was the last one available for the participant. In order to consider a questionnaire received as valid, over 50% of the items were to be completed. Calculated by the Clopper-Pearson method for each treatment group.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab at 3 mg/kg solution provided intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Everolimus provided in 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG001","title":"Everolimus"}],"paramType":"NUMBER","populationDescription":"All randomized participants; any participants that was randomized to any treatment group in the study.","reportingStatus":"POSTED","timeFrame":"from randomization up to disease progression or death (approximately up to 105 Months)","title":"Percentage of Participants With Disease-related Symptom Progression (DRSP)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}